Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Receivables (2021 - 2025)

Historic Change in Receivables for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $19.8 million.

  • Kiniksa Pharmaceuticals International's Change in Receivables rose 34696.87% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 2291.85%. This contributed to the annual value of $20.5 million for FY2024, which is 13771.79% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Change in Receivables of $19.8 million as of Q3 2025, which was up 34696.87% from -$8.2 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Change in Receivables peaked at $25.5 million during Q1 2022, and registered a low of -$21.6 million during Q2 2022.
  • Its 5-year average for Change in Receivables is $2.9 million, with a median of $1.5 million in 2022.
  • Data for Kiniksa Pharmaceuticals International's Change in Receivables shows a peak YoY increase of 111419.05% (in 2023) and a maximum YoY decrease of 74485.23% (in 2023) over the last 5 years.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Change in Receivables (Quarter) stood at $686000.0 in 2021, then skyrocketed by 118.8% to $1.5 million in 2022, then surged by 1114.19% to $18.2 million in 2023, then dropped by 7.62% to $16.8 million in 2024, then increased by 17.8% to $19.8 million in 2025.
  • Its last three reported values are $19.8 million in Q3 2025, -$8.2 million for Q2 2025, and -$1.7 million during Q1 2025.